

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

24th September 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani
MAIL :	info@chorditherapeutics.com

Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) today announced that patient enrollment has been completed in the Initial Expansion Cohort ("IE Cohort") of the Phase 1/2 clinical trial of rogocekib being conducted in the United States.

Chordia is conducting expansion cohorts in the Phase 1/2 clinical trial of rogocekib in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in the United States.

The expansion portion of the study is designed in accordance with the U.S. Food and Drug Administration's (FDA) Project Optimus guidance and consists of two stages: the Initial Expansion Cohort ("IE Cohort") and the Additional Expansion Cohort ("AE Cohort"). The IE Cohort was initiated in March 2026. Chordia has now completed enrollment of all 28 planned patients, and the first dose has been administered to the final enrolled patient.

Chordia remains committed to advancing its development programs with patient safety as its highest priority. The Company will analyze the data obtained from the IE Cohort and continue preparations for the initiation of the AE Cohort.

This milestone represents progress in line with the Company's development plan. Chordia will promptly disclose any material developments as they arise.

About Chordia Therapeutics

Chordia Therapeutics is a research and development-stage biopharmaceutical company specializing in oncology with clinical-stage assets, headquartered in Fujisawa City, Kanagawa Prefecture. Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets

the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177) , CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chorditherapeutics.com/en/>.